Don’t perform screening tests of polymorphisms of factor V (Leiden) and Factor II (G20210A) in unselected patients, like all patients with only one episodes of venous thrombosis, in healthy subjects or in pregnant women with no specific anamnestic signs or before to start a treatment with oral contraceptives.

Don’t perform screening tests of polymorphisms of factor V (Leiden) and Factor II (G20210A) in unselected patients, like all patients with only one episodes of venous thrombosis, in healthy subjects or in pregnant women with no specific anamnestic signs or before to start a treatment with oral contraceptives.

According to national and international recommendations and guidelines, testing should not be performed outside of specific medical conditions, e.g.: episodes of venous thrombosis at an early age or the presence of strong familial history, with two or more affected...
Do not continue proton pump inhibitor (PPI) therapy chronically beyond the indications specified in the product label (e.g., 4–8 weeks for the treatment of gastroesophageal reflux disease); instead, reduce the dose (for example, from twice daily to once daily) or discontinue the PPI and use it on an as-needed basis.

Do not continue proton pump inhibitor (PPI) therapy chronically beyond the indications specified in the product label (e.g., 4–8 weeks for the treatment of gastroesophageal reflux disease); instead, reduce the dose (for example, from twice daily to once daily) or discontinue the PPI and use it on an as-needed basis.

Proton pump inhibitors (PPIs) should be used for the shortest duration possible, as long-term use (over 4–8 weeks) has been associated with increased risks of: deficiencies in essential nutrients such as calcium and vitamin B12, bone fractures, gastrointestinal...